← All indications
Peritoneal Neoplasms
Tumors or cancer of the PERITONEUM.
Subtype terms (1)
More specific conditions that are subtypes of Peritoneal Neoplasms in the MeSH hierarchy.
Drugs by status
Approved for this indication (2)
Phase 4 trials (1)
Phase 3 trials (29)
- atezolizumab
- olaparib
- urea
- irinotecan
- doxorubicin
- gemcitabine
- fluorouracil
- paclitaxel
- nintedanib
- hypericum perforatum
- phenoxodiol
- mitomycin
- pembrolizumab
- leucovorin
- oregovomab
- lanreotide
- carboplatin
- topotecan
- trabectedin
- capecitabine
- docetaxel
- sodium thiosulfate
- oxaliplatin
- cisplatin
- letrozole
- epothilone
- relacorilant
- Modified RNA Vaccine Against Influenza
- ly4170156
Phase 2 trials (46)
- methylprednisolone
- galunisertib
- Abagovomab
- epoetin
- catumaxomab
- cixutumumab
- durvalumab
- enzastaurin
- farletuzumab
- gl-onc1
- nivolumab
- indocyanine green
- octreotide
- pasireotide
- pegaspargase
- pemetrexed
- ipilimumab
- rintatolimod
- s-1
- celecoxib
- cetuximab
- birinapant
- tremelimumab
- tumor necrosis factor
- dendritic cells
- volociximab
- vandetanib
- gefitinib
- autologous cytokine induced killer cells
- gimeracil
- +16 more
Phase 1 trials (22)
Organizations
Organization Involved with Phase 3 Indications (73)
- Foundation Medicine
- Amgen
- Clovis Oncology
- Roche
- Merck
- Eli Lilly
- Ipsen
- Novartis
- Boehringer Ingelheim
- PharmaMar
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- ZonMw: The Netherlands Organisation for Health Research and Development
- Medical Research Council
- National Cancer Institute (NCI)
- Huazhong University of Science and Technology
- Ziekenhuis Oost-Limburg
- Maastricht University
- Hebei University
- Cornell University
- First People's Hospital of Foshan
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Guangxi Medical University
- Guangzhou Medical University
- Gynecologic Oncology Group
- Hasselt University
- Jiangmen Central Hospital
- NRG Oncology
- Nordic Society for Gynaecologic Oncology
- Stanford University
- Sichuan University
- +43 more
Organization Involved with Phase 2 Indications (96)
- Incyte
- Genelux
- Facet Biotech
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Imclone
- Morphotek
- AstraZeneca
- Centocor
- Genentech
- Aventis
- Pfizer
- Sanofi
- Biogen
- AIO-Studien-gGmbH
- EGEN, Inc.
- Galenic Research Institute Ltd
- GlaxoSmithKline
- Northwest Biotherapeutics
- Shenzhen SiBiono GeneTech Co.,Ltd
- VentiRx Pharmaceuticals Inc.
- Neovii Biotech
- National Institutes of Health (NIH)
- Mount Sinai Hospital, Canada
- University of Pennsylvania
- University of Arizona
- University of Pittsburgh
- Baylor University
- Canadian Cancer Trials Group
- Case Western Reserve University
- +66 more
Organization Involved with Phase 1 Indications (42)
- AbbVie
- Biomarin
- Intrexon
- Celgene
- Sanofi-Aventis
- Areva Med LLC
- CritiTech, Inc.
- ImmunoVaccine Technologies, Inc.
- Kyowa Hakko Kirin
- Sorrento Therapeutics, Inc.
- Otsuka
- Boston University
- Duke University
- Ludwig Institute for Cancer Research
- McMaster University
- University of Lausanne
- Wayne State University
- Yale University
- University of California, San Francisco
- University of Utah
- IRCCS CANDIOLO
- National University of Singapore
- The University of Hong Kong
- City of Hope National Medical Center
- Ruhr University Bochum
- Lee's Pharmaceutical
- University of Massachusetts
- Immunotope
- Cancer Center of Kansas
- University of Alabama, Birmingham
- +12 more
Organization Involved with Other Experimental Indications (5)